Innate Pharma (IPHA) Receivables - Net (2017 - 2025)

Innate Pharma has reported Receivables - Net for 9 years, with the latest figure at $14.7 million in Q4 2025.

• For the quarter ending Q4 2025, Receivables - Net fell 3.63% year-over-year to $14.7 million; the trailing twelve-month figure through Dec 2025 stood at $14.7 million (down 3.63% YoY), and the FY2025 full-year result was $14.7 million, down 3.63% from the prior year.
• Receivables - Net for Q4 2025 stood at $14.7 million, up from $5.6 million in the prior quarter.
• The five-year high for Receivables - Net was $65.7 million in Q2 2022, with the low at $5.6 million in Q2 2025.
• Historically, Receivables - Net has averaged $40.7 million across 5 years, with a median of $53.9 million in 2021.
• Annual changes were most pronounced in 2021 — Receivables - Net tumbled 99.66% — and 2022, when it climbed 20.83%.
• Innate Pharma's Receivables - Net stood at $55.2 million in 2021, then decreased by 3.04% to $53.5 million in 2022, then gained by 11.72% to $59.8 million in 2023, then plunged by 74.44% to $15.3 million in 2024, then dropped by 3.63% to $14.7 million in 2025.
• The last three Receivables - Net figures came in at $14.7 million (Q4 2025), $5.6 million (Q2 2025), and $15.3 million (Q4 2024), per Business Quant data.